bioRxiv / medRxiv
open access
Evaluating prescriber preferences for the treatment of indeterminate Chagas disease (EPPIC study): an international survey
BackgroundBenznidazole (BNZ) and nifurtimox (NFX) remain the only approved treatments for Trypanosoma cruzi infection, but both are associated with frequent adverse drug reactions (ADRs), long treatment duration, and limited accessibility, resulting in poor treatment adherence and premature disconti
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Benznidazole/Itraconazole combination treatment enhances anti-Trypanosoma cruzi activity in experimental Chagas disease.#1272166
- Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease#1378811
- Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease#1073200
- Single Ascending Dose Safety Study of Oxfendazole#1369617
- BENDITA BEnznidazole New Doses Improved Treatment and Associations#812064
Record · ID 1394091
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive